Published in March 2015
Analysis of 24-h Holter recordings was a substudy of SHIFT to explore the heart rhythm safety of ivabradine and to determine effects of ivabradine on 24-h, daytime, and night-time heart rate compared with resting office heart rate. 298 patients with ivabradine and 304 patients with matching placebo were assessed over 8 months.1
The study confirmed that the heart rate reduction with  ivabradine was similar in resting office and in 24-h, awake, and asleep recordings, with beneficial effects on heart rate variability and no meaningful increases in supraventricular or ventricular arrhythmia.

1. Bohm M et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. Eur J Heart Fail. 2015 Mar 20. [Epub ahead of print]